Company / PP&E (Net)
aTYR PHARMA INC PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$4.3M
FY2025
5-year range
$543.0K / $5.5M
FY2021-FY2025
Trend
-12.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +36.5%.
Declined from $6M to $4M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +11.7%
- 5-Year CAGR
- +36.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +36.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 12.1% year-over-year.
- Peak pp&e (net) was recorded in FY2023.
- Lowest pp&e (net) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | -12.1% |
| FY2024 | $4.8M | -12.3% |
| FY2023 | $5.5M | +80.8% |
| FY2022 | $3.1M | +463.4% |
| FY2021 | $543.0K | -39.6% |
| FY2020 | $899.0K | -29.2% |
| FY2019 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026